ClearPoint Neuro (ClearPoint Neuro) Change In Working Capital : $-0.36 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Change In Working Capital?

ClearPoint Neuro's change in working capital for the quarter that ended in Dec. 2023 was $1.11 Mil.

ClearPoint Neuro's change in working capital for the fiscal year that ended in Dec. 2023 was $-0.36 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ClearPoint Neuro Change In Working Capital Historical Data

The historical data trend for ClearPoint Neuro's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Change In Working Capital Chart

ClearPoint Neuro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.91

-2.69

-1.68

-4.29

-0.36

ClearPoint Neuro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.13	-1.77	-0.25	0.54	1.11

ClearPoint Neuro Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.36 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ClearPoint Neuro Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ClearPoint Neuro (ClearPoint Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075

Website

https://www.clearpointneuro.com

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.

Executives

Lynnette C Fallon	director	108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau	director	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra	officer: Chief Operating Officer	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett	director, officer: CEO and President	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall	officer: GM, Biologics & Drug Delivery	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro	officer: Vice President, Finance	5 MUSICK, IRVINE CA 92618
Harold A Hurwitz	officer: Chief Financial Officer
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R	director	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards	director	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc.	10 percent owner	75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners	officer: Vice President, Marketing	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103